Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 45

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 8
Chunk 45
---
 currently have an indeterminable contractual term, and 50,000 warrants issued to underwriters as
    part of the IPO with a remaining contractual life of 2.65 years. In connection with the IPO in February 2024, the Company issued
    50,000 warrants to purchase common stock to the IPO underwriter (or its designees) at an exercise price of $7.00. These warrants
    are exercisable immediately and will expire in the four-and-a-half-year period commencing six months after the February 2024 IPO.
    The warrants will be exercisable at any time and from time to time, in whole or in part. The warrants provide for registration rights
    (including a one-time demand registration right and piggyback registration rights that expire 5 years from the commencement of sales
    of the offering) and customary anti-dilution provisions as permitted under FINRA Rule 5110(g)(8).
  
 Private
placement Warrants

During
the year ended December 31, 2023, the Company issued to the 2023 Private Placement investors a Common Stock warrant the right to purchase
up to 268,025 shares of common stock at an exercise price of $15.42 per share. The Company also issued to the placement agent a Common
Stock warrant the right to purchase up to 67,007 shares of common stock at an exercise price of $3.73 per share. Both issuances of warrants
are immediately vested and will be exercisable any time until the day that is one year plus ninety days from the date an IND filing is
made with the FDA.

2023
Omnibus Incentive Plan

In
December 2023, the Company’s Board of Directors adopted the Company’s 2023 Omnibus Incentive Plan, (“2023 Omnibus Plan”).
The 2023 Omnibus Plan authorizes the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code,
to the Company’s employees and any of its parent and subsidiary corporations’ employees, and for the grant of nonstatutory
stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to the Company’s
employees, directors, and consultants and any of its future subsidiary corporations’ employees and consultants

The
2023 Omnibus Plan provides that 6,500,000 shares of the Company’s Common Stock are reserved for issuance under the 2023 Omnibus